CordenpharmaCordenPharma is pleased to announce that their CordenPharma Chenôve (France) manufacturing facility recently completed an FDA Inspection and received a successful response with no 483s reported.

The last FDA Inspection took place in 2014.

Yves Michon, Managing Director of CordenPharma Chenôve, comments: “We are pleased with the outcome of the FDA Inspection in August 2016, as it reflects our willingness to comply with the highest level of cGMP regulatory compliance while continuously improving our standards for our customers and their projects going forward.”

CordenPharma Chenôve, one of multiple CordenPharma facilities across Europe and the US, is a cGMP manufacturer of APIs and advanced pharmaceutical intermediates, specializing in the design of synthetic routes and development processes for new products, with equipment and chemical technologies particularly suitable for multistep synthesis from laboratory to commercial scale.